Astrana Health, Inc. (NASDAQ:ASTH) Receives Consensus Rating of “Buy” from Analysts

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $65.17.

A number of equities research analysts have commented on ASTH shares. Robert W. Baird increased their target price on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. BTIG Research lifted their price objective on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 3rd. Stifel Nicolaus boosted their target price on shares of Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. KeyCorp assumed coverage on shares of Astrana Health in a research note on Friday, October 11th. They set a “sector weight” rating on the stock. Finally, TD Cowen initiated coverage on shares of Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 price target for the company.

Astrana Health Trading Up 2.6 %

NASDAQ:ASTH opened at $42.11 on Friday. Astrana Health has a 1 year low of $32.32 and a 1 year high of $63.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The stock has a fifty day moving average price of $54.61 and a two-hundred day moving average price of $47.81. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of 32.39, a PEG ratio of 1.90 and a beta of 1.24.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.33 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.33. The firm had revenue of $478.71 million during the quarter, compared to analysts’ expectations of $462.01 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. During the same period in the previous year, the firm posted $0.47 earnings per share. As a group, sell-side analysts anticipate that Astrana Health will post 1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

Several institutional investors and hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC acquired a new position in shares of Astrana Health during the 3rd quarter valued at $34,000. Nisa Investment Advisors LLC purchased a new stake in shares of Astrana Health in the third quarter worth about $35,000. KBC Group NV acquired a new stake in shares of Astrana Health in the third quarter valued at about $70,000. Quarry LP purchased a new stake in shares of Astrana Health during the 3rd quarter valued at about $77,000. Finally, Quest Partners LLC acquired a new position in Astrana Health during the 3rd quarter worth approximately $133,000. Institutional investors and hedge funds own 52.77% of the company’s stock.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.